ICON Public (NASDAQ:ICLR) Price Target Raised to $376.00

ICON Public (NASDAQ:ICLR) had its price target hoisted by Robert W. Baird from $367.00 to $376.00 in a report published on Monday, Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

A number of other equities analysts have also recently issued reports on the company. The Goldman Sachs Group started coverage on ICON Public in a report on Thursday, June 6th. They issued a buy rating and a $370.00 target price for the company. William Blair reaffirmed an outperform rating on shares of ICON Public in a report on Friday, May 31st. Evercore ISI lowered their target price on ICON Public from $350.00 to $330.00 and set an outperform rating for the company in a report on Friday, April 26th. Mizuho reiterated a buy rating and issued a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Finally, TD Cowen upped their price target on ICON Public from $349.00 to $373.00 and gave the company a buy rating in a research report on Friday, May 31st. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, ICON Public has a consensus rating of Moderate Buy and a consensus target price of $346.20.

ICON Public Price Performance

ICON Public stock opened at $328.65 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. ICON Public has a 52 week low of $221.20 and a 52 week high of $344.77. The stock has a market capitalization of $27.11 billion, a P/E ratio of 39.98, a price-to-earnings-growth ratio of 1.43 and a beta of 1.23. The stock has a fifty day moving average of $317.57 and a 200-day moving average of $304.28.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $3.38 EPS for the quarter, topping analysts’ consensus estimates of $3.30 by $0.08. ICON Public had a return on equity of 11.70% and a net margin of 8.30%. The company had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.09 billion. On average, sell-side analysts expect that ICON Public will post 14.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bruce G. Allen Investments LLC bought a new position in ICON Public in the fourth quarter worth approximately $25,000. Livelsberger Financial Advisory bought a new position in ICON Public in the fourth quarter worth approximately $29,000. Pinnacle Bancorp Inc. boosted its holdings in ICON Public by 110.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 105 shares of the medical research company’s stock worth $30,000 after acquiring an additional 55 shares in the last quarter. Riverview Trust Co bought a new position in ICON Public in the first quarter worth approximately $31,000. Finally, GAMMA Investing LLC bought a new position in ICON Public in the fourth quarter worth approximately $37,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.